Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

BACKGROUND: Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the two strategies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuchen, Liu, Panpan, Cai, Jun, Jing, Hongmei, Zou, Liqun, Huang, Huiqiang, Wu, Yuanbin, Li, Wenyu, Zhong, Liye, Jin, Xueli, Ye, Xu, Feng, Ru, Zhang, Huilai, Zhang, Liling, Lin, Lie, Sun, Xiuhua, Tian, Yuyang, Xia, Zhongjun, Li, Zhiming, Huang, He, Xia, Yi, Cai, Qingqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678091/
https://www.ncbi.nlm.nih.gov/pubmed/35438258
http://dx.doi.org/10.1002/cam4.4765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678091/
https://www.ncbi.nlm.nih.gov/pubmed/35438258
http://dx.doi.org/10.1002/cam4.4765

Ejemplares similares